Literature DB >> 6093838

Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma.

D Tait, M J Peckham, W F Hendry, P Goldstraw.   

Abstract

Of a total of 307 patients treated with chemotherapy for advanced non-seminomatous germ-cell testicular tumours between 1976 and 1983, 73 (23.8%) had masses excised after treatment. Resected tissue showed residual malignancy in 16 (22%), fibrosis and necrosis in 25 (34%) and differentiated (mature teratoma) in 32 (44%). Of the 16 patients with tumour only 7 (44%) are alive and disease-free compared with 21/25 (84%) and 27/32 (84%) for fibrosis/necrosis and differentiated teratoma respectively. In addition to histological evidence of residual tumour, elevated serum markers at the time of surgery and/or incomplete excision of residual masses were adverse prognostic features. Of 12 patients with differentiated teratoma or fibrosis who had incomplete resections or densely adherent masses excised with difficulty, 7 subsequently relapsed. The majority of differentiated teratoma patients (75%) had evidence of differentiation in their primary tumours; 88% showed cystic change in metastases and almost one-third showed an increase in the size of metastases during chemotherapy. The data suggest that post-chemotherapy surgery may have a therapeutic as well as a diagnostic role and that complete excision of residual disease should be attempted even if resection at one site has shown either fibrosis or differentiated teratoma. The significance of these findings in relation to treatment induced differentiation is discussed.

Entities:  

Mesh:

Year:  1984        PMID: 6093838      PMCID: PMC1976989          DOI: 10.1038/bjc.1984.226

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  A primary malignant testicular tumour with unusual metastases.

Authors:  M Duari
Journal:  Br J Clin Pract       Date:  1967-04

2.  Maturation in human tumours.

Authors:  D W Smithers
Journal:  Lancet       Date:  1969-11-01       Impact factor: 79.321

3.  Proceedings: Distribution of retroperitoneal lymph node metastases in testicular germinal tumors.

Authors:  B Ray; S I Hajdu; W F Whitmore
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

4.  Histologically benign teratoid metastasis of testicular embryonal carcinoma: report of five cases.

Authors:  G W Willis; S I Hajdu
Journal:  Am J Clin Pathol       Date:  1973-03       Impact factor: 2.493

5.  Combination chemotherapy in germinal cell tumors.

Authors:  M L Samuels; V J Lanzotti; P Y Holoye; L E Boyle; T L Smith; D E Johnson
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

6.  Letter: Benign transformation of testicular carcinoma by chemotherapy.

Authors:  C Merrin; G Baumgartner; Z Wajsman
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

7.  Metastatic teratocarcinoma following chemotherapy. Maturation to a mass pathologically indistinguishable from a mediastinal enteric cyst.

Authors:  B Stechmiller; P H Wiernik; M Shin; J Satterfield
Journal:  Chest       Date:  1976-05       Impact factor: 9.410

8.  The role of surgery in the combined management of metastases from malignant teratomas of testis.

Authors:  W F Hendry; A Barrett; T J McElwain; D M Wallace; M J Peckham
Journal:  Br J Urol       Date:  1980-02

9.  The evolution of mature teratoma from malignant testicular tumors.

Authors:  W K Hong; R E Wittes; S T Hajdu; E Cvitkovic; W F Whitmore; R B Golbey
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

10.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

View more
  18 in total

1.  Disorders of ejaculation.

Authors:  W F Hendry
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

Review 2.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

3.  Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors.

Authors:  Jörg Thomas Hartmann; Oliver Rick; Karin Oechsle; Markus Kuczyk; Thomas Gauler; Patrick Schöffski; Jan Schleicher; Frank Mayer; Reinhard Teichmann; Lothar Kanz; Carsten Bokemeyer
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Remission of recurrent mature teratoma with interferon therapy.

Authors:  D Ornadel; A Wilson; C Trask; J Ledermann
Journal:  J R Soc Med       Date:  1995-09       Impact factor: 5.344

5.  Iatrogenic damage to male reproductive function.

Authors:  W F Hendry
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

6.  Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis.

Authors:  R J Zuk; B J Jenkins; J E Martin; R T Oliver; S I Baithun
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 7.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 8.  Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer.

Authors:  Stephen D W Beck; Richard S Foster
Journal:  World J Urol       Date:  2006-03-08       Impact factor: 4.226

Review 9.  The role of high-dose chemotherapy in relapsed germ cell tumors.

Authors:  O Rick; C Kollmannsberger; J T Hartmann; T Braun; W Siegert; C Bokemeyer; J Beyer
Journal:  World J Urol       Date:  2004-03-18       Impact factor: 4.226

10.  Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.

Authors:  Eduardo de Paula Miranda; Daniel Kanda Abe; Adriano João Nesrallah; Sabrina Thalita dos Reis; Alexandre Crippa; Miguel Srougi; Marcos Francisco Dall'Oglio
Journal:  World J Surg Oncol       Date:  2012-09-28       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.